176 related articles for article (PubMed ID: 36497412)
1. CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells.
Terenziani R; Galetti M; La Monica S; Fumarola C; Zoppi S; Alfieri R; Digiacomo G; Cavazzoni A; Cavallo D; Corradi M; Tiseo M; Petronini PG; Bonelli M
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497412
[TBL] [Abstract][Full Text] [Related]
2. Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
Bonelli MA; Digiacomo G; Fumarola C; Alfieri R; Quaini F; Falco A; Madeddu D; La Monica S; Cretella D; Ravelli A; Ulivi P; Tebaldi M; Calistri D; Delmonte A; Ampollini L; Carbognani P; Tiseo M; Cavazzoni A; Petronini PG
Neoplasia; 2017 Aug; 19(8):637-648. PubMed ID: 28704762
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Cyclin Dependent Kinase 4/6 Overcomes Primary Resistance to Programmed Cell Death 1 Blockade in Malignant Mesothelioma.
Jang HJ; Truong CY; Lo EM; Holmes HM; Ramos D; Ramineni M; Lee JS; Wang DY; Pietropaolo M; Ripley RT; Burt BM; Lee HS
Ann Thorac Surg; 2022 Nov; 114(5):1842-1852. PubMed ID: 34592265
[TBL] [Abstract][Full Text] [Related]
4. Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.
Bonelli M; Terenziani R; Zoppi S; Fumarola C; La Monica S; Cretella D; Alfieri R; Cavazzoni A; Digiacomo G; Galetti M; Petronini PG
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708306
[No Abstract] [Full Text] [Related]
5. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
Zanellato I; Colangelo D; Osella D
Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
[TBL] [Abstract][Full Text] [Related]
6. Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma.
Karatkevich D; Deng H; Gao Y; Flint E; Peng RW; Schmid RA; Dorn P; Marti TM
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233258
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition.
Paternot S; Raspé E; Meiller C; Tarabichi M; Assié JB; Libert F; Remmelink M; Bisteau X; Pauwels P; Blum Y; Le Stang N; Tabone-Eglinger S; Galateau-Sallé F; Blanquart C; Van Meerbeeck JP; Berghmans T; Jean D; Roger PP
Mol Oncol; 2024 Apr; 18(4):866-894. PubMed ID: 36453028
[TBL] [Abstract][Full Text] [Related]
8. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
Iwahori K; Serada S; Fujimoto M; Ripley B; Nomura S; Mizuguchi H; Shimada K; Takahashi T; Kawase I; Kishimoto T; Naka T
Int J Cancer; 2013 Jan; 132(2):459-71. PubMed ID: 22532243
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
Moriya M; Yamada T; Tamura M; Ishikawa D; Hoda MA; Matsumoto I; Klepetko W; Oda M; Yano S; Watanabe G
Oncol Rep; 2014 Mar; 31(3):1109-15. PubMed ID: 24378576
[TBL] [Abstract][Full Text] [Related]
10. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
Hoda MA; Mohamed A; Ghanim B; Filipits M; Hegedus B; Tamura M; Berta J; Kubista B; Dome B; Grusch M; Setinek U; Micksche M; Klepetko W; Berger W
J Thorac Oncol; 2011 May; 6(5):852-63. PubMed ID: 21358348
[TBL] [Abstract][Full Text] [Related]
11. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.
Fennell DA; King A; Mohammed S; Greystoke A; Anthony S; Poile C; Nusrat N; Scotland M; Bhundia V; Branson A; Brookes C; Darlison L; Dawson AG; Gaba A; Hutka M; Morgan B; Bajaj A; Richards C; Wells-Jordan P; Thomas A;
Lancet Oncol; 2022 Mar; 23(3):374-381. PubMed ID: 35157829
[TBL] [Abstract][Full Text] [Related]
12. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells.
Nguyen DM; Schrump WD; Chen GA; Tsai W; Nguyen P; Trepel JB; Schrump DS
Clin Cancer Res; 2004 Mar; 10(5):1813-25. PubMed ID: 15014036
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with
Malignant Pleural Mesothelioma].
Zeng X; Jiang Z; Duan J
Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):7-13. PubMed ID: 35078279
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Koda Y; Kuribayashi K; Doi H; Kitajima K; Nakajima Y; Ishigaki H; Nakamura A; Minami T; Takahashi R; Yokoi T; Kijima T
Oncology; 2021; 99(3):161-168. PubMed ID: 33053560
[TBL] [Abstract][Full Text] [Related]
16. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
Green J; Dundar Y; Dodd S; Dickson R; Walley T
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD005574. PubMed ID: 17253564
[TBL] [Abstract][Full Text] [Related]
18. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
Yamaji M; Ota A; Wahiduzzaman M; Karnan S; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Haniuda M
Cancer Med; 2017 Nov; 6(11):2646-2659. PubMed ID: 28960945
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
Borchert S; Wessolly M; Schmeller J; Mairinger E; Kollmeier J; Hager T; Mairinger T; Herold T; Christoph DC; Walter RFH; Eberhardt WEE; Plönes T; Wohlschlaeger J; Aigner C; Schmid KW; Mairinger FD
BMC Cancer; 2019 Jan; 19(1):108. PubMed ID: 30700254
[TBL] [Abstract][Full Text] [Related]
20. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]